Vitrolife Interim Report January -- June 2004
17. August 2004 03:25 ET
|
Vitrolife
STOCKHOLM, Sweden, Aug. 17, 2004 (PRIMEZONE) -- Vitrolife:
- Turnover increased by 13 percent, to SEK 55.1 million (48.8). Adjusted for currency effects the increase was 16 percent. During the...
Vitrolife Receives Patent Approval in USA
16. August 2004 03:19 ET
|
Vitrolife
STOCKHOLM, Sweden, Aug. 16, 2004 (PRIMEZONE) -- Vitrolife has been notified that the company's patent application, regarding the use of recombinant albumin with or without hyaluronic acid in media...
Vitrolife Products Receive European Approval
28. Juni 2004 02:27 ET
|
Vitrolife
STOCKHOLM, Sweden, June 28, 2004 (PRIMEZONE) -- Vitrolife has received European approval (CE mark) for a complete series of products within ART (Assisted Reproductive Technology). "This gives us...
Anna Ahlberg New CFO at Vitrolife AB (publ)
22. Juni 2004 09:54 ET
|
Vitrolife
STOCKHOLM, Sweden, June 22, 2004 (PRIMEZONE) -- Anna Ahlberg has been appointed as Head of Vitrolife's accounting and financing department and for investor relations.
Anna Ahlberg has worked within...
Vitrolife: Date of 2003 Year-End Report
02. Februar 2004 13:36 ET
|
Vitrolife
STOCKHOLM, Sweden, Feb. 2, 2004 (PRIMEZONE) -- Vitrolife's year end report for 2003 will be presented the 17th of February instead of the earlier date preliminary set (12th February) due to a change...
Vitrolife sells cross-linked hyalonic-acid subsidiaries for 7 million USD plus royalty to Mentor Corp., U.S.A.
26. August 2003 03:46 ET
|
Vitrolife
STOCKHOLM, Sweden, August 26, 2003 (PRIMEZONE) -- Vitrolife AB announced today that it has completed the sale of two of its subsidiaries, A-Life Ltd and A-Life Inc, to Mentor Corporation, a global...
Dr. Magnus Nilsson CEO of Vitrolife
13. August 2003 10:56 ET
|
Vitrolife
STOCKHOLM, Sweden, Aug. 13, 2003 (PRIMEZONE) -- The Board of Directors appointed Dr. Magnus Nilsson CEO of Vitrolife AB (publ). Magnus Nilsson was previously Acting CEO of Vitrolife since January 3,...
Vitrolife receives FDA marketing approval of EmbryoGlue -- a Breakthrough in ART (Assisted Reproductive Technology)
09. Juli 2003 08:23 ET
|
Vitrolife
STOCKHOLM, Sweden, July 9, 2003 (PRIMEZONE) -- The American Food and Drug Administration (FDA) has approved Vitrolife's application for market clearance, 510(k), for EmbryoGlue(R) developed in close...
Vitrolife launches EmbryoGlue -- A Breakthrough in ART (Assisted Reproductive Technology)
26. Mai 2003 08:39 ET
|
Vitrolife
STOCKHOLM, Sweden, May 26, 2003 (PRIMEZONE) -- EmbryoGlue(R) is an implantation promoting medium for transfer of embryos back into the woman, with physical properties more similar to the uterine...
Vitrolife announces issuance of patent for new cell cryopreservation technique
10. März 2003 12:46 ET
|
Vitrolife
STOCKHOLM, Sweden, March 10, 2003 (PRIMEZONE) -- Vitrolife (Stockholm:VITR) inventors have been granted a U.S. Patent for a new cryopreservation technique for viable cells, called loop vitrification....